                                                                                                                                ARTICLE
Haploinsufficiency TAB2 Causes
Congenital Heart Defects Humans
Bernard Thienpont,1,14 Litu Zhang,2,15 Alex V. Postma,3 Jeroen Breckpot,1 Le Charles Tranchevent,4
Peter Van Loo,5,6 Kjeld MÃ¸llgaËšrd,7 Niels Tommerup,2 Iben Bache,2 Zeynep Tu  Â¨ mer,2,8
Klaartje van Engelen, BjoÂ¨rn Menten, Geert Mortier,
                     9                10             10,11 Darrel Waggoner, Marc Gewillig,13
                                                                            12
             4                  1
Yves Moreau, Koen Devriendt, Lars Allan Larsen    2,*

Congenital heart defects (CHDs) common major developmental anomalies frequent cause perinatal
mortality, etiology remains obscure. identiï¬?ed locus CHDs 6q24-q25. Genotype-phenotype correlations 12 patients carrying chromosomal deletion 6q delineated critical 850 kb region 6q25.1 harboring ï¬?ve genes. Bioinformatics
prioritization candidate genes locus role CHDs identiï¬?ed TGF-b-activated kinase 1/MAP3K7 binding protein 2 gene
(TAB2) ranking candidate gene. role candidate gene cardiac development supported conserved
expression developing human zebraï¬?sh heart.  critical, dosage-sensitive role development demon-
strated cardiac defects observed titrated knockdown tab2 expression zebraï¬?sh embryos. deï¬?nitively conï¬?rm role candidate gene CHDs, performed mutation analysis TAB2 402 patients CHD, revealed evolu-
tionarily conserved missense mutations. Finally, balanced translocation identiï¬?ed, cosegregating familial CHD. Mapping breakpoints demonstrated translocation disrupts TAB2. Taken  data clearly demonstrate role TAB2 human cardiac development.


Introduction                                                                   accommodate limitations, attempted                                                                             alternative approach identifying loci associated Congenital heart defects (CHDs) single impor-                  CHDs chromosomal rearrangements. strat-
tant congenital cause perinatal mortality mor-                      egy enables identiï¬?cation regions harboring genes
bidity,1,2 despite manifest importance, etiology             involved heart development dosage-sensitive man-
remains largely obscure. epidemiological studies                   ner construction human morbidity map demonstrated certain environmental factors                     CHDs. previously reported identiï¬?cation tributory,3 family twin studies suggest major genetic                 candidate loci CHD screening patients
component.4,5  mutations genes asso-                 CHD means array comparative genome
ciated monogenic CHDs, mainly linkage anal-                    hybridization (aCGH).10,11 delinea-
ysis large families CHD segregates auto-                tion characterization loci, located somal-dominant trait.6 Given mortality associated                  chromosome 6q24-q25 containing MAP3K7IP2
CHDs, large families rare. family studies                 (TAB2 [MIM 605101]) gene. TAB2 maps critical
suggest partially penetrant causes CHDs                    region deleted patients CHD, dosage-sensitive common purely monogenic causes,7,8 loci                      zebraï¬?sh development, speciï¬?cally expressed remained unidentiï¬?ed linkage studies. result,                  human zebraï¬?sh cardiovascular  causative genes identiï¬?ed, mutation                  disrupted balanced trans-
analyses shown account small                 location family members CHD fraction (< 1 ) CHD cases,9 representing limita-               mutated 402 patients CHDs, providing
tion genetic counseling CHD patients                    strong evidence TAB2 major role cardiac
families elucidation pathogenesis CHD.                 development.



1
  Laboratory Genetics Human Development, Department Human Genetics, University Leuven, B3000 Leuven, Belgium; 2Wilhelm Johann-
sen Centre Functional Genome Research, Department Cellular Molecular Medicine, University Copenhagen, DK-2200 Copenhagen,
Denmark; 3Department Anatomy & Embryology, Heart Failure Research Center, L2-108-2, Academic Medical Center Meibergdreef 15, 1105 AZ Amster-
dam, Netherlands; 4Department Electrical Engineering ESAT-SCD, University Leuven, B3000 Leuven, Belgium; 5Department Human Genetics,
University Leuven, B3000 Leuven, Belgium; 6Department Molecular Developmental Genetics, VIB, B3000 Leuven, Belgium; 7Developmental
Biology Unit, Department Cellular Molecular Medicine, University Copenhagen, DK-2200 Copenhagen, Denmark; 8Applied Human Molecular
Genetics, Kennedy Center, DK-2600 Glostrup, Denmark; 9Department Cardiology Clinical Genetics, Academic Medical Centre, 1105 AZ Amster-
dam, Netherlands; 10Center Medical Genetics, Ghent University Hospital, B9000 Ghent, Belgium; 11Department Medical Genetics, Antwerp
University Antwerp University Hospital, B2160 Antwerpen, Belgium; 12Department Pediatrics Department Genetics University Chi-
cago, Chicago, 60637, USA; 13Paediatric Cardiology Unit, University Hospitals Leuven, B3000 Leuven, Belgium
14
   Present address: Laboratory Molecular Signalling & Laboratory Developmental Genetics Imprinting, Babraham Institute, Cambridge
CB22 3AT, UK
15
   Present address: Guangxi Cancer Institute, Afï¬?liated Cancer Hospital, Guangxi Medical University, 530000 Nanning, Guangxi, China
*Correspondence: larsal@sund.ku.dk
DOI 10.1016/j.ajhg.2010.04.011. Âª2010 American Society Human Genetics. rights reserved.




                                                                   American Journal Human Genetics 86, 839â€“849, June 11, 2010 839
 Subjects Methods                                                   Sanger Institute) chosen chromosomes 6 2 tiling
                                                                       resolution (set obtained BACPAC Chori, Oakland, CA, USA).
Patients                                                               244K arrays obtained Agilent hybridized according
Informed consent obtained patients legal         manufacturerâ€™s protocol. Genomic DNA labeled guardians investigations patient material anony-        BioPrime Array CGH Genomic Labeling (Invitrogen,
mous publication. Syndromic CHD patients (Table S1, available          Carlsbad, CA, USA) use Cy3- Cy5-labeled dCTPs
online) followed Pediatric Cardiology Unit         (20 -deoxycytidine 50 -triphosphate) (Amersham Biosciences,
Clinical Genetics Unit University Hospitals Leuven (patient     Boston, MA, USA) recommended manufacturer , Clinical Genetics Unit Ghent University Hospital     minor modiï¬?cations.15
(patient F), described (patients B, C, .12 Patients      Translocation breakpoints mapped ï¬‚uorescence situ
isolated CHDs (Table S2) followed Pediatric Cardiology     hybridization (FISH) analysis use 200 ng BAC DNA
Unit University Hospitals Leuven collected          according standard procedures. FISH signals visualized
CONCOR national registry database DNA bank.13 Patients             avidin-FITC detection  Chromosomes coun- CHD translocation identiï¬?ed systematic reex-        terstained DAPI (4,6-diamino-2-phenylindole), amination carriers balanced translocations.14 Patients      signals investigated Leica DMRB epiï¬‚uorescence
isolated CHDs investigated aCGH. studies             microscope equipped Sensys 1400 CCD camera (Photomet- approved local ethics committees.                          rics, Tucson, AZ, USA) IPLab Spectrum imaging software
                                                                       (Abbott Laboratories, Abbott Park,  USA).

Tissue Samples Immunohistochemistry Analysis
Human embryonic tissues collected legal abortions.           Candidate-Gene Prioritization
Informed consent obtained according Helsinki Declara-       Candidate-gene prioritization performed use tion II. Embryonic age based crown-rump length measure-         adapted version Endeavour.16 brief, data sources ment. Tissue samples dissected appropriate tissue blocks     prioritization added regular set data sources: ï¬?xed 12â€“24 hr 4 C 10  neutral buffered formalin, 4      expression microarray data set murine heart development
Formol-Calcium, Lillieâ€™s Bouinâ€™s ï¬?xatives. specimens    (GEO accession number GSE1479â€”transposed human gene
dehydrated graded alcohols, cleared xylene, embedded       identiï¬?ers use BioMart) set representing gene parafï¬?n. Serial sections, 3â€“5 mm  cut transverse,     homology, extracted HomoloGene, BioMart, Inpara-
sagittal, horizontal planes placed silanized slides.         noid. data summarized vector representations,
   Sections deparafï¬?nized rehydrated xylene followed       scoring use Pearson correlation. Addi- series graded alcohols accordance established          tionally, prioritizations based data sources displaying
procedures. sections treated fresh 0.5  solution       strong Spearman rank correlation (> 0.3) fused prior fusing hydrogen peroxide methanol 15 min quenching           results prioritizations based independent data
endogenous peroxidase rinsed TRIS buffered            sources (Figure S1). Data sources validated leave saline (TBS, 5 mM Tris-HCl, 146 mM NaCl, pH 7.6). Nonspeciï¬?c           cross-validation (LOOCV) described previously,16 sources
binding inhibited incubation 30 min blocking           area curve 0.6 omitted (Figure S2).
buffer (ChemMate antibody diluent S2022, DakoCytomation,               Genes prioritized basis seven training sets
Glostrup, Denmark) room temperature. sections              (Table S5), representing discrete aspects cardiac development incubated overnight 4 C polyclonal rabbit antibody     genetics, results seven sets fused speciï¬?cally recognizes human TAB2 (MAP3K7IP2),                use rank-order statistics.16 silico testing LOOCV demon-
immunoblotting immunohistochemistry (ARP32402, Aviva               strated adapted algorithm readily ranks genes Systems Biology, 1:1000) blocking buffer (ChemMate antibody         established involvement heart development, average diluent S2022, DakoCytomation).                                        5 . 105 annotated protein-coding genes 6q24-
   sections washed TBS incubated            q25 prioritized. Gene identiï¬?cation prioritization 30 min peroxidase-labeled anti-rabbit polymer (DAKO             based Ensembl Release 49 Endeavour databases EnVision Ã¾ HRP K4011, DakoCytomation). sections             2008. washed TBS, followed incubation 10 min 3,30 -diamino-benzidine chromogen solution. Positive staining
                                                                       Zebraï¬?sh Assays recognized brown color. sections dehydrated                                                                        Wild-type (AB) ï¬‚k-green ï¬‚uorescent protein (ï¬‚k-GFP)17 zebra-
graded alcohols followed xylene coverslipped DPX
                                                                       ï¬?sh (Danio rerio) stocks maintained accordance stan-
mounting media. Nonimmune rabbit IgG1 (X0936) staining
                                                                       dard aquaculture guidelines. Eggs collected natural primary antibody used negative controls. Sections
                                                                       mating 30 min laid timed development human embryos containing osteoclasts served positive
                                                                       assured. RNA extracted TRIzol, cDNA controls. Control sections stained antibody                                                                        synthesized random primers Superscript III kit  nonimmune rabbit IgG1 blank, stained osteoclasts
                                                                       Invitrogen, Merelbeke, Belgium). positive.
                                                                          mount situ hybridizations (WISH) wild-type                                                                        ï¬‚k-GFP zebraï¬?sh embryos performed described previ-
Molecular Cytogenetics                                                 ously18 use sequence-veriï¬?ed probe ampliï¬?ed aCGH performed described15 house-created microar-         PCR synthesized cDNA. resulting embryos ray slides, constructed bacterial artiï¬?cial chromosome (BAC)      imaged embedded acrylamide-bisacrylamide gel, cryosec- P1-derived artiï¬?cial chromosome (PAC) probes chosen              tioned 20 mm, mounted vectabond-pretreated micro- genome-wide manner 1 Mb spacing (set donated             scope slides. Sections rehydrated phosphate-buffered



840 American Journal Human Genetics 86, 839â€“849, June 11, 2010
                                                                                                                         Figure 1. Fine Mapping Chromosome        q24.1             q24.2     q24.3         q25.1             q25.2                   q25.3                      Aberrations 6q24-q25, Candidate-
 140Mb                       145Mb            150Mb                       155Mb                        160Mb            Gene Prioritization
                                                                                                                          Position deletions patients
                                                                           J                                          CHD (red bars) CHD
                                         B                                             K                                (black bars). Deletion reference letters                                                           C                                                             shown bars. Regions containing
                                              D                    G                                                  deletion breakpoints shown gray.
                                                                 E                                                      Phenotypes shown Table S1. Deletion
                                               F                                                                        F male mother,
                                                                             H                                          affected CHDs. critically
                                                                                                                        deleted region CHDs demarcated B           149.25                   149.50               149.75                    150.00                              light red box.
                                                                                                                        (B) Position deletions                  UST                                      TAB2             PPIL4      KATNA1   LATS1    PCMT1   LRP11
                                                                                                                        region deleted CHD patients (com-
                                                          SUMO1 ZC3H12D            C6orf72      NUP43                   monly deleted region) respect                                                                                                                       11 annotated genes encoded     B                                                                                                                   region. deletion patient H
    C                                                                                                                   (black, CHD) does affect TAB2
    D                                                                                                                   gene, demarcates critically
    E                                                                                                                   deleted region, contains ï¬?ve genes.
    F                                                                                                                   arrow indicates position                                                                                                                 H       translocation breakpoint chromosome
                                                      N                                                                 6 family N.



saline 0.1  Tween 20 (PBT) incubated 4 hr PBT-                      tional studies, present results mutation
1  preimmune donkey serum (PDS) room temperature                               analysis. overnight 4 C Alexa-647-labeled GFP antibody
(sc-9996 AF647 Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1/200 PBT-1  PDS). Slides washed times                           Molecular Characterization Deletions 6q24-q25
PBT, mounted vectashield-DAPI, imaged Olympus                            observed deletions 6q24-q25 multiple syndromic
FV1000 confocal imaging Olympus AX51 bright-                           CHD patients. framework aCGH screening
ï¬?eld imaging.
                                                                                      study,4 aCGH 1Mb arrays revealed presence    Morpholinos (MOs) designed intron 2-exon 3
                                                                                      6q24.2-q25.1 deletion patient  shown splice site (50 -ATC ACT CTT GTT CTG AGG AAA GAA G-3,
                                                                                      occurred novo rtqPCR analysis parental DNA.
splice-site-blocking MO [sbMO]) translation initiation
site (50 -ATC TGC TGG TTT CCC TGT GCC ATT C-30 , translation-                         Patient aortic coarctation, hypoplastic aortic
blocking MO [tbMO]) tab2. MOs control MO                                arch, ventricular septal defect, additional
(cMO) (50 -CCT CTT ACC TCA GTT ACA ATT TAT 30 )                                problems. routine analysis patients ordered Gene Tools (Philomath,  USA). Fidelity anno-                       unexplained syndromic disorder, second deletion tated nucleotide sequences MO binding sites conï¬?rmed                        detected delineated patient Fp use Agi-
direct sequencing. MOs diluted 1/50 Rhodamine solu-                         lent 44K arrays. shown rtqPCR inherited
tion, estimated 0.5 nL injected                          mother (Fm). mother (Fm) diagnosed cell stage speciï¬?ed doses. tab2 mRNA concentrations                           childhood aortic mitral valve stenosis measured real-time quantitative (rtq) PCR described previ-
                                                                                      episodes sinus tachycardia. studies prompted
ously15 normalized b-actin.
                                                                                      perform echocardiographic evaluation patient
                                                                                      Fp, revealed mild centrovalvular insufï¬?ciency Mutation Analysis                                                                     aortic pulmonary valves. Previously reported inter-
DNA collected patients outï¬‚ow tract defect                           stitial 6q deletions (patients B, C, 12 (tetralogy Fallot [ToF], pulmonic stenosis [PS], aortic stenosis                   delineated aCGH 244K arrays. Genotype data  ). Exons exon-intron boundaries TAB2 ampliï¬?ed
                                                                                      patients (D, E, G, H, J, K) collected PCR use oligonucleotide primers described Table
                                                                                      literature reports12,19â€“23 online database car-
S3. PCR products sized DNA gel electrophoresis                                                                                       diogenetics, CHDWiki.24 extent deletions sequenced BigDye DNA sequencing kit (Applied Biosys-
tems, Foster City, CA, USA).                                                          presence absence CHDs deletion carriers 
                                                                                      picted Figure 1A, detailed phenotype                                                                                       genotype data provided Table S1.
Results                                                                                  Cardiac defects identiï¬?ed deletion patients                                                                                       affected outï¬‚ow tract. included stenosis present identiï¬?cation delineation locus                           heart valves, hypoplasia aortic arch, CHDs, candidate gene selected                               atrial ventricular septal defects. Patients larger dele- locus. investigated role gene                             tions typically mild mental retardation addi-
heart development expression analyses func-                               tional congenital problems, smaller


                                                                          American Journal Human Genetics 86, 839â€“849, June 11, 2010 841
 deletions (patients Fp, Fm, J) (low) normal mental                                     B
development. Genotype comparison CHD patients
revealed commonly deleted region 1.2 Mb, affecting                                                                  EC
11 genes (Figure 1B). Deletion H, patient CHD, demarcates 850 kb region
deleted CHD patients unaffected patients                                   B
 CHD. critically deleted region extends 149.09 149.96 Mb (Figure 1B) contains ï¬?ve                                                                       EC
                                                                             Tr
genes unaffected deletion H.


Prioritization Genes 6q24-q25 CHD                      C                                  D clustering CHD-associated deletions 6q24-q25
suggested haploinsufï¬?ciency genes                           Ao
 locus causes CHDs. putative CHD                       D           gene likely resides commonly deleted region, exclude alternative hypothesis                   Ve genes located 6q24-q25 cause
CHDs incomplete penetrance. silico analysis extended genes 6q24-q25. addi-
tion, extension test set enabled better assess-
ment statistical power ï¬?ndings. Gene prioriti-
zation yielded ranked list candidate genes CHDs,        Figure 2. TAB2 Expression Human Embryonic Hearts
                                                                   Section 5.5 wk embryo. TAB2 expression (brown color) MAP3K7IP2  known TAB2) ranking ï¬?rst          prominent ventricular trabeculae endocardial
105 genes 6q24-q25 (Table S4 Figure S3). cor-       cushions outï¬‚ow tract.
responding p value (4.17 3 107) highly signiï¬        (B) Magniï¬?cation endocardial cushions. located critically deleted region, signiï¬   (C) Frontal section 7.5 wk embryo.
                                                                 (D) Magniï¬?cation showing cytoplasmic expression TAB2 prioritization (p < 0.01) obtained gene     endothelial cells lining developing aortic valves. commonly deleted region. genome-wide prioriti-          Abbreviations follows:  atrium; Ao, aorta; EC, endocardial
zation, TAB2 ranks 44th genes          cushions; Tr, trabeculae; Ve, ventricle.
human genome (Table S6). like likely
candidate gene CHDs.                                            investigate function tab2 zebraï¬?sh
                                                                 development, knocked expression using
                                                                 independent MOs interfering TAB2 Expression Human Embryonic Hearts                        normal splicing translation tab2 RNA. Injection explore potential role TAB2 candidate gene      resulted similar developmental abnormalities,
human heart development, analyzed expression           injection cMO did human embryos. Immunohistochemistry analysis tissue           result abnormal development. Knockdown sections 5.5 wk 7.5 wk human embryos showed             demonstrated speciï¬?c. ï¬?rst embryological defects
cytoplasmic expression TAB2 cells ventricular       apparent gastrulation (Figures 4F 4G)
trabeculae (Figure 2A), endothelial cells conotrun-    included delayed epiboly progression convergent
cal cushions outï¬‚ow tract (Figures 2A 2B),        extension defects. Later development (36â€“48 hpf), endothelial cells lining developing aortic valves     severe heart failure apparent (Figures 4D 4E):
(Figures 2C 2D). results indicate function        heart tube appeared elongated, blood
TAB2 developing human heart.                              pooling common cardinal vein entry                                                                  heart.
tab2 Zebraï¬?sh Assays                                                molecular effect sbMO injection splicing used zebraï¬?sh model organism investigate          nascent tab2 RNA investigated PCR cDNA
role dosage sensitivity tab2 vertebrate devel-     injected embryos (Figure 4B). Sequencing RT-PCR
opment. WISH staged wild-type zebraï¬?sh embryos                products revealed transcript lacking wild-type exon
revealed ubiquitous tab2 expression early devel-          3 formed treatment, resulting frameshift
opment (12â€“18 hr postfertilization [hpf])             premature stop codon starting seventh nucle-
restricted expression pattern later development,          otide wild-type exon 4 (Figure 4A). sbMO-generated expression developing cardiac outï¬‚ow tract,          transcript encodes 95  truncated variant dorsal aorta, posterior cardinal vein (Figure 3).    normal protein. conï¬?rmed similar phenotype expression pattern reminiscent expression         observed tbMO injection, represents loss- human heart development suggests                 function situation. relative correctly conserved role tab2 cardiac outï¬‚ow tract.           spliced mRNA assessed rtqPCR cDNA reverse


842 American Journal Human Genetics 86, 839â€“849, June 11, 2010
                                                                                                                 C




                                                                                                                  Câ€™

     12hpf                        18hpf                     24hpf
                                                                                       B


                                                                                                                  Câ€™â€™
                                                                                                        Câ€™â€™â€™



     30hpf                        55hpf                     72hpf

Figure 3. Gene Expression tab2 Developing Zebrafish
mRNA expression tab2 developing zebraï¬?sh distinct developmental stages (indicated lower left corner). Boxed parts embryos 30 hpf 55 hpf repeated   (C000 ), respectively.
 : Magniï¬?cation showing expression tab2 dorsal aorta (arrow) posterior cardinal vein (arrowhead).
(B) Transverse section hindbody zebraï¬?sh 30 hpf depicted  , showing restricted expression dorsal aorta
(arrowhead) posterior cardinal vein (arrow).
(C): Bright-ï¬?eld image expression tab2 cardiac outï¬‚ow tract 55 hpf (arrow).
(C0 ) DAPI staining section depicted (C) (pseudocolored blue).
(C00 ) section depicted (C), immunostained Alexa-647-labeled GFP antibody (pseudocolored red), displaying position cardiac outï¬‚ow tract (arrow).
(C000 ) Image 55 hpf, mount-stained embryo, presenting orientation section shown (C), (C0 ), (C00 ) (white line).


transcribed RNA extracted sbMO-                      protein function (Figure 5C). DNA samples injected embryos 20 hpf. revealed sbMO injec-              phenotypic data available family members tion resulted dose-dependent reduction normal                   patients L M. mutations   absent
splicing (Figure 4C). Phenotypes apparent dose              658 ethnically matched control chromosomes. 2 3 ng, corresponding 41  58  reduction normal expression, showing haploinsufï¬?ciency
                                                                        Investigation Family t(2;6) Translocation tab2 causes developmental defects (Figures 4Câ€“4I).
                                                                        CHD
                                                                        family CHD segregating t(2;6)(q21;q25)
Sequence Analysis TAB2 Human Patients                             translocation previously identiï¬?ed.14 family Outï¬‚ow Tract Defects                                               (family N), translocation carriers history TAB2 relevant spatiotemporal expression                   CHD (Figure 5D). Patient N-II.2 diagnosed pattern dosage-sensitive role development,                  aortic stenosis atrial ï¬?brillation age 67 required good candidate gene explaining CHDs                  aortic valve replacement. Patient N-III.1 diagnosed
evident deletion 6q24-q25. conï¬?rm                    aortic stenosis age 2 yrs. aortic valve role TAB2 CHDs, analyzed DNA sequence                  surgically replaced age 25. age 34 hospitalized TAB2 402 patients outï¬‚ow tract defects                       paroxysmal supraventricular tachycardia. died (Table S2). patients analyzed aCGH.                   age 49 myocardial infarction. Patient N-III.2 Sequencing analysis revealed heterozygous missense                  diagnosedâ€” like mother sister cardiac
mutations TAB2 gene. female (patient L) carried              rhythm problems (sick sinus syndrome, tachycardia). c.622C>T mutation, causing p.Pro208Ser mutation                      refused participate clinical exam- protein level (Figures 5A 5C). left-               inations investigated echocardiography.
ventricular outï¬‚ow tract obstruction, subaortic stenosis                 translocation segregating family bal-
(subAS) ï¬?bromuscular shelf, residual aortic regur-             anced, demonstrated aCGH 1Mb arrays gitation, atrial ï¬?brillation died 61 years age            chromosome 6 2 tiling microarrays (data shown). heart failure. Patient M carried c.688C                  FISH studies positioned translocation breakpoint
mutation, causing p.Gln230Lys mutation protein                 2q21 14.2 kb region chromosome position
level (Figure 5B). bicuspid aortic valve                131,691,033-131,705,253, disrupting POTEE gene
aortic dilation. mutations alter highly conserved resi-            (encoding prostate, ovary, testis-expressed protein E).
dues predicted detrimental effects                   position translocation breakpoint 6q25


                                                                American Journal Human Genetics 86, 839â€“849, June 11, 2010 843
                                   1105kb                                   1110kb                   1115kb                      1120kb
     chr20
                                                                     tbMO sbMO
      tab2
isoform 1
isoform 2
    sbMO
 injec 

                                                           100 
                                    wt-spliced tab2 mRNA
                 marker
          sbMO
    wt




B                               C                                                                 D                          Dâ€™
                                     relave quanty 
                                                           80 
                          2
                          1.5                              60 
                          1
                          0.8                              40 
                          0.6                                                                     E                          Eâ€™
                                                           20 
                          0.4
                                                            0 
                                                                   0 0.5 1 2 3
                          0.2                                          ng MO injected



F                                                                                                       G
                                                                                                                            12hpf
                                                                                                        100 
                                                                                                            80 
                                                                                                            60 
                                                                                                            40 
                                                                                                            20 
                                                                                                             0 
                                                                                                                     4ng 2ng 1ng 0ng
         Class                    Class II                      Class II            Class III                          C C-II C-III

H                                                                                                                         20hpf
                                                                                                            100 
                                                                                                            80 
                                                                                                            60 
                                                                                                            40 
                                                                                                            20 
                                                                                                             0 
     Class                    Class II                           Class III          Class IV                           4ng 2ng 1ng 0ng
                                                                                                                   C      C-II C-III C-IV
Figure 4. tab2 Knockdown Zebrafish
  Schematic organization tab2 gene zebraï¬?sh genome. alternative splice isoforms detected PCR reverse-
transcribed mRNA shown. Introns dotted lines, exons boxes (coding sequences black, noncoding sequences orange). 


844 American Journal Human Genetics 86, 839â€“849, June 11, 2010
                    C                                                                   D                                            



                                            208




                                                                        230
                    Human IHGVPPPVLNSPQGNSIYIRP YITTPGGTTRQTQQHSGWVSQFN P
TAACAGTCCACAGGG
         c.622C>T       Cat IHGVPPPVLNSPQGNSIYIRP YITTPGGTARQTQQHSGWVSQFN P                       1                 2   3        4
                     Mouse IHGVPPPVLNSPQGNSIYIRP YITTPSGTARQTQQHSGWVSQFN P
                                                                                                                                      II
                  Armadillo IHGVPPPVLNSPQGNSIYIRP YITTPSGTARQTQQHSGWVSQFN P
                   Platypus IHGVPPPALNSPQGNSIYIRP YITAPSGTSRQAQQPPGWVSQLSP                                              *
                    Chicken IHGVPPPVLNSPQGNSIYIRP YITAPSGTARQTQQQAGWASQFNP
                                             5

B               Zebra Finch IHGVPPPVLNSPQGNSIYIRP YITAPSGTARQTQQQPGWASQFNP                                          1       2    3
                   Xenopus IHGVPPPILNSPHGNSIYIRP YVTSQSGTARQAQQSPSWVSHN-P                                                             III
                 Tetraodon IHGGPQSGLSSPLGNSIYIRP FVS-QSGSSRLSQQ-QGGRAQYSP                                       *       *
                                                                                               Aorc stenosis
ACAGACACAACAGCA        Fugu IHGGPQSGLSSPQGNSIYIRP YVS-QSGTSRLNQQ-QGGRAQYSP                     Aorc valve
                  Zebraï¬?sh IHGGPQSGLNSP--NSIYIRP YVT-QPGSTRQVQC----RAQYSP                      replacement
        c.688C Mutaons              S                      K                                Arrhythmia                             IV
                                                                                               Transloca                                                                                            *   t(2:6) carrier


Figure 5. TAB2 Mutated Disrupted CHD Patients
 B) Partial TAB2 reference-sequence-read traces corresponding traces missense mutations identiï¬?ed patients L M
(phenotypes detailed main text).
(C) Conservation mutated residues tetrapod ï¬?sh lineages. TAB2 lower lineages; mutated residues conserved paralogous TAB3.
(D) Pedigree family N. Translocation carriers marked, breakpoint chromosome 6 disrupts TAB2. Phenotypes annotated insert detailed main text.


lies 17 kb region chromosome position                    preferences. TAB2 ranked ï¬?rst (p Â¼ 4.17 3 107)
149,678,240-149,695,219, ï¬?rst intron, ï¬?rst                candidate genes (Figure 1C). Importantly,
exon, promoter region TAB2 (Figure S4).                        genes commonly deleted
                                                                     region generated signiï¬ signal involvement
                                                                     heart development use method (p >
Discussion                                                           0.03 .
                                                                        Support involvement TAB2 human heart identiï¬?ed locus CHDs 6q24-q25,                  development provided expression deleted seven individuals CHD (Figure 1A).              gene developing human zebraï¬?sh embryos.
search genes causing CHDs region, prior-           TAB2 expressed endothelial lining devel-
itized 105 genes chromosome 6q24 6q25               oping human heart: detected expression endothelial involvement heart development, using tool                 cells lining trabeculae developing aortic valves
based established genomic data fusion algorithm.16             (Figure 2). Endocardial cushions involved endothe- strategy ensures gene selection inï¬‚uenced               lial-mesenchymal transformation, important event minor extent researcherâ€™s prior knowledge             development cardiac valves outï¬‚ow


target sites sbMO) tbMO indicated double arrowheads. lower schema indicates effect sbMO injection mature tab2 mRNA (isoforms 1 2).
(B) Gel electrophoresis product PCR cDNA extracted nonmorphant (WT) 2 ng sbMO-injected zebraï¬?sh embryos
24 hpf DNA marker size comparison, showing band 2000 bp wild-type situation, additional frag-
ments morphant situation.
(C) Effect TAB2 sbMO injection correctly spliced mRNA.
(D) Wild-type AB embryo 48 hpf.
(D0 ) Noninjected embryo 48 hpf expressing GFP vascular endothelial cells inï¬‚uence ï¬‚k promoter (ï¬‚k-GFP).
(E) Morphant embryo 48 hpf. Note enlarged pericardial sac (arrow).
(E0 ) Morphant ï¬‚k-GFP embryo 48 hpf. Note elongated heart.
(F) Phenotypical classiï¬?cation sbMO-injected zebraï¬?sh embryos 12 hpf. Defects epiboly progression evident, progression yolk-syncytial layer schematically displayed  Phenotypes ordered severe normal. Class  anterior-posterior
gradient evident. Class II: yolk-syncytial layer progresses vegetal pole; different embryos shown illustrate continuum phenotypes class II. Class III: wild-type. Left, posterior;  dorsal.
(G) Distribution phenotypes 12 hpf dependent sbMO dose injected. Y axis: percentage embryos class indi-
cated color code. X axis: TAB2 sbMO injected cell stage. 42 embryos successfully injected dose. total, 230 embryos successfully injected.
(H) Phenotypical classiï¬?cation sbMO-injected zebraï¬?sh embryos 24 hpf. Phenotypes ordered severe normal. Class 
death. classes described main text. Lateral images:  anterior.
  Distribution phenotypes 24 hpf dependent sbMO dose injected. Y axis: percentage embryos class. X axis: TAB2 sbMO injected cell stage. 42 embryos successfully injected dose. total, 230 embryos successfully injected. Injection 4 ng cMO did increase frequency abnormal phenotypes comparison noninjected 0 ng-injected control embryos  shown).



                                                             American Journal Human Genetics 86, 839â€“849, June 11, 2010 845
 tract.25 conservation Tab2 expression devel-        abnormal somites, small head comparison oping cardiovascular mouse26 zebra-         control larvae.  early defects observed ï¬?sh (Figure 3) supports functional relevance       embryos preclude conclusive analysis involve-
TAB2 cardiovascular development.                               ment tab2 heart development: hearts
   TAB2 (TAK1 binding protein 2) encodes protein        morphant embryos abnormally structured studied mainly role inï¬‚ammatory response.          heart failure evident enlarged pericardial sac
TAB2 causes autophosphorylation activation                 (Figure 4E), exclude effect sec-
mitogen-activated protein kinase kinase kinase 7 (MAP3K7,         ondary earlier defects gastrulation. reports known TAK1 [MIM 602614]),27  media-          similarly shown knockout genes involved tors TNF-receptor-associated factors [TRAFs]          isolated CHDs humans cause pleio-
receptor-interacting proteins [RIPs]) relaying signals       tropic phenotype zebraï¬?sh.33 probably attribut-
receptors chemokines (TNF, LPS, IL1) extracel-      able species-speciï¬?c differences; example, lular signaling molecules (TGF-b Wnt) downstream           epibolic movements direct correlate proteins IKK, p38, JNK, RCAN, NLK. TAK1 conse-        mammalian development.  clear dosage
quently modulates activity molecules NF-kB,        sensitivity tab2 zebraï¬?sh demonstrates b-catenin, NFAT, HDAC3 downstream target            proper tab2 dosage critical normal development
genes. Tak1/ mice die embryonic day 10.5                 vertebrates.
(E10.5) E12.5 neural tube cardiovascular             ï¬?ndings conï¬?rmation defects.28,29 Xie colleagues (2006)30 generated mice          role TAB2 CHD, investigated presence cardiac-speciï¬?c expression dominant-negative          germline mutations CHD patients. revealed Tak1, showing inhibiting Tak1 function heart          missense mutations affecting evolutionarily highly 
leads altered electrical conduction (shortened PR interval),   served residues (Figures 5Aâ€“5C). conserved residues
impaired ventricular ï¬?lling, cardiac hyperthropy. Inter-      recognized protein domain, affect
estingly, authors discussed unpublished results     hitherto described protein binding sites; future
showed cardiac-speciï¬?c deletion Tak1 causes midges-       studies need establish function conserved
tation death.30 Zhang colleagues (2000)31 reported         domain. observed paucity mutations unex-
mice cardiac-speciï¬?c expression activated Tak1,           pected given known etiological genetic heteroge-
showing develop cardiac hypertrophy. Combined,          neity CHDs: mutations genes established results demonstrate altered Tak1 signaling      role CHD development similarly small
heart leads cardiac disorders.  aCGH        (< 1 ) fraction CHD patients.9 Furthermore, screening study led identiï¬?cation presented    CHD phenotypes investigated, exclude
TAB2 deletion, identiï¬?ed 650 kb TAK1 duplication          TAB2 mutations associated additional CHD girl pulmonary stenosis (data shown).           phenotypes.  identiï¬?ed family duplication inherited mother,             CHD cardiomyopathy cosegregate balanced
cardiac defect. brother died early childhood           translocation 2q21 6q25. Family members severe pulmonary valve stenosis             carry translocation CHD.
DNA available study.                                      breakpoint 2q21 disrupts POTEE gene (Figure S4),
   Tab2/ mice die E12.5 display severe liver         seven poorly conserved paralogues recently
degeneration increased hepatocyte apoptosis.              expanded gene family.34 Given genes immunological hematological problems described            expressed mammalian heart POTEE vari- patients TAB2 disruption. Interestingly,          able copy number normal human population, 70  Tab2Ã¾/ mice die 1 wk birth.              unlikely disruption POTEE causes observed
reason increased mortality established.32        CHDs family. breakpoint 6q25 located obviously precludes direct phenotypic             TAB2, leads disruption, support-
comparison human hemizygous patients, does                ing role TAB2 pathogenesis CHD. Taken
demonstrate Tab2 dosage sensitive mouse             results demonstrate perturbations excellent candidate explaining CHDs             mutations TAB2 causing CHDs.
observed patients.                                            described CHDs outï¬‚ow tract
   investigate dosage sensitivity tab2,      defects, exclude phenotypic spectrum
titrated knockdown tab2 gene expression              extends   patient C presented atrial
MO injection. observed phenotypic changes                 septum defect (ASD) patient E ventricular septal fraction normal tab2 mRNA approximately halved,            defect (VSD) (Table S1). surprising, given
demonstrating tab2 gene dosage sensitive         large variation CHD phenotypes zebraï¬?sh. morphants displayed early embryo-            described genetic syndromes. classic example
logical defects (delayed epibolic movements gastru-        22q11 deletion syndrome, CHD phenotypes
lation; Figure 4F) developed larvae         include Tetralogy Fallot (ToF), pulmonary stenosis (PS), shorter dysfunctional heart, curved tail,        interrupted aortic arch, VSD, ASD, cardiac


846 American Journal Human Genetics 86, 839â€“849, June 11, 2010
 malformations.35 examples include Wolf-Hirchhorn                  CHDWiki, homes.esat.kuleuven ~bioiuser/chdwiki
syndrome, patients ASD, PS, VSD,                   Endeavour, www.esat.kuleuven endeavour
patent ductus arteriosus,36 Smith-Magenis syndrome,                 Gene expression omnibus (GEO), www.ncbi.nlm.nih.gov/geo valvular abnormalities, ASD, VSD, ToF                      Homologene, www.ncbi.nlm.nih.gov/homologene
                                                                        Inparanoid, inparanoid.sbc.su.se reported.37 Variable CHD phenotypes                                                                         Online Mendelian Inheritance Man (OMIM), www.ncbi.nlm.
observed patients gene mutations. Examples                                                                           nih.gov/Omim
plenty include patients JAG1 mutations, PS, aortic stenosis, VSD, ASD 
ported,38 patients CITED2 mutations,                   Accession Numbers
present ASD, VSD, ToF, transposition great
                                                                        GenBank accession numbers human TAB2 cDNA arteries.39 Patients NOTCH1 mutations present
                                                                        protein sequences reported paper NM_015093.3  VSD, ToF, double outlet right ventricle,                                                                         NP_055908.1. Human zebraï¬?sh genome coordinates risk late-onset complications                                                                         numbered according March 2006 human reference
aortic valve calciï¬?cation  requiring valve replace-              sequence (NCBI build 36.1) July 2007 zebraï¬?sh (Danio 
ment,40 observed patient N-II.3.                              rio) Zv7 assembly.
   conclusion, demonstrated ability posi-
tional cloning strategy identiï¬?cation genes
involved human heart defects. strategy presented                 References enables rapid, generic, powerful positional
                                                                         1. Hoffman, J , Kaplan, S. (2002). incidence congen-
cloning led identiï¬?cation gene involved                     ital heart disease. J.  Coll. Cardiol. 39, 1890â€“1900. CHD, TAB2. gene expressed developing                   2. Thom, T., Haase, N., Rosamond, W., Howard, V.J., Rumsfeld, J.,
heart, dosage sensitive zebraï¬?sh development,                     Manolio, T., Zheng, J., Flegal, K., Oâ€™Donnell, C., Kittner, S., mutated, deleted, disrupted translocation                     et al., American Heart Association Statistics Committee CHD patients.                                                               Stroke Statistics Subcommittee. (2006). Heart disease                                                                             stroke statisticsâ€”2006 update: report American
Supplemental Data                                                           Heart Association Statistics Committee Stroke Statistics
Supplemental Data include ï¬?gures tables             Subcommittee. Circulation 113, e85â€“e151. article online http://www.ajhg.org.                   3. Jenkins, K.J., Correa, , Feinstein, J , Botto, L., Britt, E.,
                                                                            Daniels, S.R., Elixson, M., Warnes, C , Webb, C.L.,
                                                                            American Heart Association Council Cardiovascular
Acknowledgments                                                             Disease Young. (2007). Noninherited risk factors                                                                             congenital cardiovascular defects: current knowledge: scien-
B.T. supported Ph.D. fellowship Agentschap voor
                                                                            tiï¬?c statement American Heart Association Council
Innovatie door Wetenschap Technologie (IWT). P.V.L. post-
                                                                            Cardiovascular Disease Young: endorsed doctoral researcher, K.D. senior clinical investigator, J.B.                                                                             American Academy Pediatrics. Circulation 115, 2995â€“3014.
aspirant investigator Research Foundation-Flanders (FWO).
                                                                         4. Calcagni, G., Digilio, M.C., Sarkozy, , Dallapiccola, B., L L. supported Danish Heart Foundation                                                                             Marino, B. (2007). Familial recurrence congenital heart
Novo Nordisk Foundation. work supported OT/O2/
                                                                            disease: overview review literature. Eur. J. Pediatr.
40, GOA/2006/12, Centre Excellence SymBioSys (EF/05/007)
                                                                            166, 111â€“116. University Leuven Belgian program                                                                          5. Manning, N., Archer, N. (2006). study determine Interuniversity Poles Attraction (IUAP), ProMeta, GOA Ambior-
                                                                            incidence structural congenital heart disease monochor-
ics, GOA MaNet, START 1, FWO (G.0318.05, G.0254.05,
                                                                            ionic twins. Prenat. Diagn. 26, 1062â€“1064.
G.0553.06, G.0302.07, ICCoS, ANMMM, MLDM, G.0733.09,
                                                                         6. Pierpont, M.E., Basson, C.T., Benson, D.W. Jr., Gelb, B.D.,
G.082409), IWT (Silicos, SBO-BioFrame, SBO-MoKa, TBM-IOTA3),
                                                                            Giglia, T.M., Goldmuntz, E., McGee, G., Sable, C , Srivas-
IUAP P6/25 BioMaGNet, ERNSI (FP7-HEALTH CHeartED).                                                                             tava, D., Webb, C.L., American Heart Association Congen-
Wilhelm Johannsen Centre Functional Genome Research                                                                             ital Cardiac Defects Committee, Council Cardiovascular
established Danish National Research Foundation. thank
                                                                            Disease Young. (2007). Genetic basis congenital
D. Stainier sharing transgenic ï¬‚k-GFP zebraï¬?sh, S. 
                                                                            heart defects: current knowledge: scientiï¬?c statement schhammer  Ilgun technical assistance, Leuven
                                                                            American Heart Association Congenital Cardiac Defects
Aquatic Facility excellent ï¬?sh care.
                                                                            Committee, Council Cardiovascular Disease Young:
                                                                            endorsed American Academy Pediatrics. Circulation
Received: November 15, 2009
                                                                            115, 3015â€“3038.
Revised: April 12, 2010
                                                                         7. Burn, J., Brennan, P., Little, J., Holloway, S., Coffey, R., Somer-
Accepted: April 20, 2010
                                                                            ville, J., Dennis, N.R., Allan, L., Arnold, R., Deanï¬?eld, J.E., et al.
Published online: 20, 2010
                                                                            (1998). Recurrence risks offspring adults major heart
                                                                            defects: results ï¬?rst cohort British collaborative study.
Web Resources                                                               Lancet 351, 311â€“316.
                                                                         8. Whittemore, R., Wells, J , Castellsague, X. (1994). second- URLs data presented follows:
                                                                            generation study 427 probands congenital heart defects
BioMart, www.ensembl.org/biomart                                            837 children. J.  Coll. Cardiol. 23, 1459â€“1467.



                                                               American Journal Human Genetics 86, 839â€“849, June 11, 2010 847
  9. Posch, M.G., Perrot, , Schmitt, K., Mittelhaus, S., Esenwein,                 abnormal karyotype, mental retardation, dysmorphic
    E.M., Stiller, B., Geier, C., Dietz, R., Gessner, R., Ozcelik, C.,              features.  J. Med. Genet.  140, 2180â€“2187.
    Berger, F. (2008). Mutations GATA4, NKX2.5, CRELD1,                21.   Osoegawa, K., Vessere, G.M., Utami, K.H., Mansilla, M ,
    BMP4 infrequently patients congenital                     Johnson, M.K., Riley, B.M., Lâ€™Heureux, J., Pfundt, R., Staaf, J.,
    cardiac septal defects.  J. Med. Genet.  146A, 251â€“253.                    van der Vliet, W , et al. (2008). Identiï¬?cation novel candi-
10. Erdogan, F., Larsen, L , Zhang, L., Tu  Â¨ mer, , Tommerup, N.,              date genes associated cleft lip palate using array
    Chen, W., Jacobsen, J.R., Schubert, M., Jurkatis, J., Tzschach,                 comparative genomic hybridisation. J. Med. Genet. 45, 81â€“86.
    , et al. (2008). High frequency submicroscopic genomic               22.   Nagamani, S.C., Erez, , Eng, C., Ou, , Chinault, C.,
    aberrations detected tiling path array comparative genome                    Workman, L., Coldwell, J., Stankiewicz, P., Patel, , Lupski,
    hybridisation patients isolated congenital heart                        J.R., Cheung, S.W. (2009). Interstitial deletion     disease. J. Med. Genet. 45, 704â€“709.                                            6q25.2-q25.3: novel microdeletion syndrome associated
11. Thienpont, B., Mertens, L., Ravel, T., Eyskens, B., Boshoff,                 microcephaly, developmental delay, dysmorphic features
    D., Maas, N., Fryns, J.P., Gewillig, M., Vermeesch, J.R.,                   hearing loss. Eur. J. Hum. Genet. 17, 573â€“581.
    Devriendt, K. (2007). Submicroscopic chromosomal imbal-                   23.   Pirola, B., Bortotto, L., Giglio, S., Piovan, E., Janes, , Guer-
    ances detected array-CGH frequent cause                         rini, R., Zuffardi, O. (1998). Agenesis corpus cal-
    genital heart defects selected patients. Eur. Heart J. 28,                   losum Probst bundles owing haploinsufï¬?ciency     2778â€“2784.                                                                      gene 8 cM region 6q25. J. Med. Genet. 35, 1031â€“1033.
12. Nowaczyk, M.J., Carter, M.T., Xu, J., Huggins, M., Raca, G.,              24.   Barriot, R., Breckpot, J., Thienpont, B., BroheÂ´e, S., Van Vooren,
    Das, S., Martin, C.L., Schwartz, S., Rosenï¬?eld, R., Wagg-                   S., Coessens, B., Tranchevent, L.C., Van Loo, P., Gewillig, M.,
    oner, D.J. (2008). Paternal deletion 6q24.3: new congenital                   Devriendt, K., Moreau, Y. (2010). Collaboratively charting
    anomaly syndrome associated intrauterine growth                            gene phenotype network human congenital heart
    failure, early developmental delay characteristic facial                    defects. Genome Med 2, 16.
    appearance.  J. Med. Genet.  146, 354â€“360.                           25.   Kirby, M.L. (2007). Cardiac Development (Oxford, New York:
13. van der Velde, E.T., Vander, V.E., Vriend, J.W., Mannens,                       Oxford University Press).
    M.M., Uiterwaal, C.S., Brand, R., Mulder, B.J. (2005).                26.   Orelio, C., Dzierzak, E. (2003). Identiï¬?cation 2 novel
    CONCOR, initiative national registry                           genes developmentally regulated mouse aorta-gonad-
    DNA-bank patients congenital heart disease                       mesonephros region. Blood 101, 2246â€“2249.
    Netherlands: rationale, design, ï¬?rst results. Eur. J. Epide-          27.   Xia, P., Sun, L., Chen, X., Pineda, G., Jiang, X., Adhikari, ,
    miol. 20, 549â€“557.                                                              Zeng, W., Chen, J. (2009). Direct activation protein
14. Bache, , Hjorth, M., Bugge, M., Holstebroe, S., Hilden, J.,                   kinases unanchored polyubiquitin chains. Nature 461,
    Schmidt, L., Brondum-Nielsen, K., Bruun-Petersen, G., Jensen,                   114â€“119.
    P.K., Lundsteen, C., et al. (2006). Systematic examination          28.   Shim, J.H., Xiao, C., Paschal, E., Bailey, S.T., Rao, P., Hayden,
    carriers balanced reciprocal translocations: strategy                   M.S., Lee, K.Y., Bussey, C., Steckel, M., Tanaka, N., et al. (2005).
    search candidate regions common complex                             TAK1, TAB1 TAB2, plays essential role multiple
    diseases. Eur. J. Hum. Genet. 14, 410â€“417.                                      signaling pathways vivo. Genes Dev. 19, 2668â€“2681.
15. Menten, B., Maas, N., Thienpont, B., Buysse, K., Vandesom-                29.   Jadrich, J.L., Oâ€™Connor, M.B., Coucouvanis, E. (2006).     pele, J., Melotte, C., Ravel, T., Van Vooren, S., Balikova, ,              TGF beta activated kinase TAK1 regulates vascular develop-
    Backx, L., et al. (2006). Emerging patterns cryptic chromo-                  ment vivo. Development 133, 1529â€“1541.
    somal imbalance patients idiopathic mental retarda-               30.   Xie, M., Zhang, D., Dyck, J.R., Li, Y., Zhang, H., Morishima,
    tion multiple congenital anomalies: new series 140                     M., Mann, D.L., Taffet, G.E., Baldini, , Khoury, D.S.,     patients review published reports. J. Med. Genet. 43,                    Schneider, M.D. (2006). pivotal role endogenous TGF-
    625â€“633.                                                                        beta-activated kinase-1 LKB1/AMP-activated protein
16. Aerts, S., Lambrechts, D., Maity, S., Van Loo, P., Coessens, B.,                kinase energy-sensor pathway. Proc. Natl. Acad. Sci. USA
    Smet, F., Tranchevent, L.C., Moor, B., Marynen, P.,                   103, 17378â€“17383.
    san, B., et al. (2006). Gene prioritization genomic               31.   Zhang, D., Gaussin, V., Taffet, G.E., Belaguli, N.S., Yamada, M.,
    data fusion. Nat. Biotechnol. 24, 537â€“544.                                      Schwartz, R.J., Michael, L.H., Overbeek, P , Schneider,
17. Motoike, T., Loughna, S., Perens, E., Roman, B.L., Liao, W.,                    M.D. (2000). TAK1 activated myocardium pres-
    Chau, T.C., Richardson, C.D., Kawate, T., Kuno, J., Weinstein,                  sure overload sufï¬?cient provoke heart failure trans-
    B.M., et al. (2000). Universal GFP reporter study                    genic mice. Nat. Med. 6, 556â€“563.
    vascular development. Genesis 28, 75â€“81.                                  32.   Sanjo, H., Takeda, K., Tsujimura, T., Ninomiya-Tsuji, J., Matsu-
18. Thisse, C., Thisse, B. (2008). High-resolution situ                      moto, K., Akira, S. (2003). TAB2 essential prevention
    hybridization mount zebraï¬?sh embryos. Nat. Pro-                        apoptosis fetal liver interleukin-1 signaling.
    toc. 3, 59â€“69.                                                                  Mol. Cell. Biol. 23, 1231â€“1238.
19. Caselli, R., Mencarelli, M , Papa, F.T., Uliana, V., Schiavone,         33.   Roessler, E., Ouspenskaia, M.V., Karkera, J.D., VeÂ´lez, J , Kant-
    S., Strambi, M., Pescucci, C., Ariani, F., Rossi, V., Longo, , et al.         ipong, , Lacbawan, F., Bowers, P., Belmont, J.W., Towbin,
    (2007). 2.6 Mb deletion 6q24.3-25.1 patient                      J , Goldmuntz, E., et al. (2008). Reduced NODAL signaling
    growth failure, cardiac septal defect, upperlip asym-                  strength mutation pathway members including
    metric dysmorphic ears. Eur. J. Med. Genet. 50, 315â€“321.                        FOXH1 linked human heart defects holoprosence-
20. Bisgaard, M., Kirchhoff, M., Tu Â¨ mer, , Jepsen, B., BrÃ¸ndum-               phaly.  J. Hum. Genet. 83, 18â€“29.
    Nielsen, K., Cohen, M., Hamborg-Petersen, B., Bryndorf, T.,               34.   Bera, T.K., Zimonjic, D.B., Popescu, N.C., Sathyanarayana,
    Tommerup, N., Skovby, F. (2006). Additional chromo-                         B.K., Kumar, V., Lee, B., Pastan,  (2002). POTE,     somal abnormalities patients previously detected                      highly homologous gene family located numerous



848 American Journal Human Genetics 86, 839â€“849, June 11, 2010
     chromosomes expressed prostate, ovary, testis,                    deletion Smith-Magenis syndrome [del(17)(p11.2p11.2)].
    placenta, prostate cancer. Proc. Natl. Acad. Sci. USA                Genet. Med. 5, 430â€“434.
    99, 16975â€“16980.                                                     38. McElhinney, D.B., Krantz, D., Bason, L., Piccoli, D , Emer-
35. Ryan, K., Goodship, J , Wilson, D , Philip, N., Levy, ,          ick, K.M., Spinner, N.B., Goldmuntz, E. (2002). Analysis     Seidel, H., Schuffenhauer, S., Oechsler, H., Belohradsky, B.,            cardiovascular phenotype genotype-phenotype correla-
    Prieur, M., et 